Dr Joseph Sinkule named president and COO of Compass Biotechnologies
This article was originally published in Scrip
Compass Biotechnologies has appointed Dr Joseph Sinkule president and chief operating officer. He recently played a leading role in directing the company towards the bio betters, generic drug markets and development of biosimiliar blockbuster products. In his new role, Dr Sinkule will take charge of the hepatitis drug development programme of C-Pharma, a subsidiary of Compass.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.